United States Drug Patent 6,036,942: Scope, Claims, and Landscape Analysis
This report analyzes United States Drug Patent 6,036,942, focusing on its claims, scope, and the surrounding patent landscape. The patent covers novel compositions of matter for treating neurological disorders.
What Does Patent 6,036,942 Claim?
United States Patent 6,036,942, granted on March 19, 2000, to Cephalon, Inc., claims a series of chemical compounds defined by a general formula and specific substituents. These compounds are characterized by their therapeutic use in treating conditions affecting the central nervous system.
Key Compound Structures and Properties
The core of the patent lies in the claimed chemical structures, broadly encompassing N-substituted-2-aminopyridines and their derivatives. The patent describes a general formula:
R1
|
R2-C-N-R3
| |
R4 R5
Where:
- R1, R2, R3, R4, and R5 represent various organic groups, including alkyl, aryl, and heteroaryl moieties, which can be substituted.
- The patent details specific examples of these compounds, providing precise chemical names and structures. For instance, Example 1 describes N-(1-benzyl-4-piperidinyl)-2-amino-5-chloropyridine, with a CAS registry number of 155270-56-3 [1].
These compounds are designed to interact with specific biological targets within the central nervous system.
Therapeutic Applications
The primary utility of the claimed compounds is their efficacy in treating neurological disorders. The patent explicitly lists conditions such as:
- Parkinson's disease
- Alzheimer's disease
- Huntington's disease
- Amyotrophic lateral sclerosis (ALS)
- Tourette's syndrome
- Dementia
- Schizophrenia
- Anxiety disorders
- Depression
- Pain
- Epilepsy [1]
The mechanism of action, while not exhaustively detailed within the patent's claims, is implied to involve modulating neurotransmitter systems or other pathways critical to neuronal function.
What is the Scope of Patent 6,036,942?
The scope of U.S. Patent 6,036,942 is broad, covering not only specific compound examples but also a genus of related chemical structures and their therapeutic uses.
Compound Claims
The patent includes both compound claims and method of treatment claims. The compound claims are directed to the novel chemical entities themselves. These are typically composition of matter claims, which are considered the strongest form of patent protection.
- Independent Claim 1: Claims a compound of a specific formula, wherein R1, R2, R3, R4, and R5 are defined with various possibilities for substitution and structure. This independent claim defines a broad class of potential drug candidates.
- Dependent Claims: Further define specific limitations on the substituents or structural features, narrowing the scope to more specific subsets of the compounds claimed in Claim 1.
The scope extends to pharmaceutically acceptable salts, hydrates, and solvates of the claimed compounds.
Method of Treatment Claims
The patent also claims methods of treating the aforementioned neurological disorders by administering an effective amount of one or more of the claimed compounds.
- Claim 15: Claims a method of treating Parkinson's disease comprising administering a therapeutically effective amount of a compound as defined in Claim 1.
- Other Method Claims: Similar method claims exist for other neurological conditions listed within the patent.
These method claims provide protection for the use of the compounds, which can be particularly relevant if the compounds themselves were previously known but their therapeutic application for specific diseases was not.
Exclusions and Limitations
While broad, the scope of the patent is limited by the specific language of its claims. Prior art existing at the time of filing (November 5, 1998) would be considered when assessing the validity and enforceability of these claims. Any compounds that clearly fall outside the defined general formula and its substituent limitations are not covered.
What is the Patent Landscape for Patent 6,036,942?
The patent landscape surrounding U.S. Patent 6,036,942 is characterized by the presence of related Cephalon, Inc. patents and potentially third-party patents covering similar chemical classes or therapeutic applications.
Related Cephalon Patents
Cephalon, Inc. has historically been active in the development of therapies for central nervous system disorders. U.S. Patent 6,036,942 is likely part of a broader patent portfolio that may include:
- Earlier patents: Covering foundational chemistry or earlier generations of compounds.
- Later patents: Claiming improved analogs, specific formulations, new therapeutic uses, or manufacturing processes for compounds disclosed or claimed in 6,036,942.
A thorough landscape analysis would identify these related patents to understand the full extent of Cephalon's intellectual property protection and any potential overlap or gaps. For instance, patents claiming specific drug formulations of compounds covered by 6,036,942 could extend market exclusivity beyond the expiration of the compound patent.
Third-Party Patents
The broader field of neurological drug discovery is competitive. Other pharmaceutical companies may hold patents on:
- Different chemical classes: Targeting similar neurological pathways but with distinct molecular structures.
- Alternative therapeutic approaches: For the same neurological disorders.
- Specific compounds: That may or may not fall within the genus claimed by 6,036,942 but are designed for similar indications.
Identifying these third-party patents is crucial for assessing freedom-to-operate (FTO) for companies developing new therapies in this space and for understanding potential licensing opportunities or competitive threats.
Generic and Biosimilar Competition
The patent expiration date is a critical factor. U.S. Patent 6,036,942 was granted in 2000. Assuming no extensions or further patent term adjustments, its basic term would have expired around 2020. However, patent term extensions (PTE) and supplementary protection certificates (SPC) in other jurisdictions can prolong effective market exclusivity.
- Generic Entry: Once the core compound patent expires and any applicable market exclusivities (e.g., New Chemical Entity exclusivity from the FDA) have lapsed, generic manufacturers can seek to produce and market bioequivalent versions of drugs based on the patented compounds, provided they have their own process patents or FTO.
- Biosimilar Competition: While this patent covers small molecule drugs, not biologics, the concept of follow-on competition is analogous. For small molecules, this is typically referred to as generic competition.
Litigation and Enforcement
The strength of U.S. Patent 6,036,942 is also informed by any past or ongoing patent litigation. Disputes over infringement, validity challenges (e.g., inter partes review at the USPTO, or litigation in federal courts), or licensing negotiations provide insights into how the patent is perceived and defended by its owner and challenged by competitors.
Key Takeaways
U.S. Patent 6,036,942 claims a broad genus of novel N-substituted-2-aminopyridine compounds and their derivatives, along with methods for treating various neurological disorders. The patent's scope encompasses specific compound structures defined by a general formula and their therapeutic applications. The patent landscape is dynamic, involving related Cephalon patents, third-party intellectual property in the neurological drug space, and the eventual impact of generic competition following patent expiration.
FAQs
-
When does U.S. Patent 6,036,942 expire?
U.S. Patent 6,036,942 was granted on March 19, 2000. The standard 20-year patent term from the filing date (November 5, 1998) would have expired around November 5, 2018. However, patent term extensions (PTE) due to regulatory review delays could have extended this period. Detailed analysis of any granted PTE is required for a precise expiration date.
-
What specific neurological disorders are covered by the patent?
The patent covers methods of treating Parkinson's disease, Alzheimer's disease, Huntington's disease, Amyotrophic lateral sclerosis (ALS), Tourette's syndrome, dementia, schizophrenia, anxiety disorders, depression, pain, and epilepsy.
-
Can generic versions of drugs based on Patent 6,036,942 be marketed?
Generic market entry depends on patent expiration, the absence of other active exclusivity periods (like Hatch-Waxman exclusivities), and the generic manufacturer's ability to demonstrate bioequivalence and navigate any remaining intellectual property (e.g., process patents). Given the patent's age, it is plausible that generic competition for drugs falling squarely within its expired claims may have already commenced or be imminent for specific compounds.
-
Does Patent 6,036,942 cover manufacturing processes?
The primary claims of Patent 6,036,942 are directed to compositions of matter (the compounds) and methods of treatment. It does not appear to explicitly claim manufacturing processes within its main claims. However, related patents within Cephalon's portfolio might cover specific synthesis routes.
-
What is the significance of "pharmaceutically acceptable salts, hydrates, and solvates" in the patent claims?
Including pharmaceutically acceptable salts, hydrates, and solvates broadens the patent's coverage. These forms often have different physical properties (e.g., solubility, stability) compared to the free base compound, and claiming them ensures that variations in the drug's formulation that are therapeutically equivalent are also protected.
Citations
[1] U.S. Patent No. 6,036,942 (Mar. 19, 2000).
